Kalcijev Folinat Sandoz (Folinic Acid)

Kalcijev Folinat Sandoz provides folinic acid rescue in clinical situations where folate pathways are compromised.

• Methotrexate toxicity: reduces toxic effects and supports recovery of normal cells.
• Cancer chemotherapy regimens: serves as a rescue agent to protect healthy tissue during high‑dose antifolate treatment.
• Folate deficiency: supplies reduced folate to patients unable to convert folic acid, improving hematologic parameters.

• Folinic acid is the biologically active reduced form of folic acid that bypasses the dihydrofolate reductase step, directly entering the folate cycle. By supplying 5‑methyltetrahydrofolate, it restores DNA synthesis, repair, and methylation processes in normal cells, counteracting the inhibition caused by antifolate agents such as methotrexate and supporting cellular recovery.

Folinic acid may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Nausea or vomiting
• Diarrhea or abdominal discomfort
• Skin rash or itching
• Mild fever or chills
• Headache or dizziness
• Transient elevation of liver enzymes

Serious or Rare Side Effects

• Anaphylactic or severe allergic reactions
• Acute hypotension or shock
• Severe renal impairment
• Hemolytic anemia
• Severe neutropenia or thrombocytopenia
• Persistent high fever with organ dysfunction

When using Kalcijev Folinat Sandoz, clinicians should consider several safety measures.

• Renal function monitoring: adjust use in patients with impaired clearance.
• Hepatic function monitoring: observe liver enzyme changes.
• Hypersensitivity caution: discontinue if severe allergic signs appear.
• Concomitant methotrexate dosing: ensure appropriate timing to avoid antagonism.
• Pregnancy and lactation: evaluate risk‑benefit before administration.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Folinic acid can interact with several drug classes, requiring attention to dosing and timing.

Major Interactions (Avoid)

• High‑dose methotrexate without rescue: may negate therapeutic effect.
• Antifolate agents (pemetrexed, trimetrexate): can reduce efficacy of chemotherapy.
• Sulfonamide antibiotics: may increase risk of hypersensitivity.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may affect renal clearance.
• Penic